MedTrace Logo

Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

NCT03222622 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2018-11-14

No results posted yet for this study

Summary

This is a phase II study to evaluate the efficacy and safety of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.

Conditions

  • Mild to Moderate Psoriasis

Interventions

DRUG

Icotinib hydrochloride cream

Apply topically twice daily for 12 consecutive weeks

DRUG

Placebo cream

Apply topically twice daily for 12 consecutive weeks

Sponsors & Collaborators

  • Tigermed Consulting Co., Ltd

    collaborator INDUSTRY

  • Betta Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Min Zheng, PHD · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-29
Primary Completion
2018-08-15
Completion
2018-10-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03222622 on ClinicalTrials.gov